The biosimilar market size attained a value of USD 24.5 billion in 2023. The market is likely to grow at a CAGR of 17.60% during the forecast period of 2024-2032, likely to attain a value of USD 105.1 billion by 2032.
In June 2023, Samsung Bioepis and Biogen Inc. announced the launch of BYOOVIZ™ (ranibizumab-nuna) in the United States. The biosimilar referencing LUCENTIS® (ranibizumab)I is priced 40% lower than its biologic. It offers affordable and effective treatment to rental disorder patients. BYOOVIZ™ is also the first ophthalmology biosimilar launched in the United States, which is aimed at enhancing the accessibility of anti-VEGF treatments.
In June 2023, Amgen announced that its biosimilar to Rituxan®, RIABNI™ (rituximab-arrx), was approved by the US FDA to treat all available Rituxan® indications. The approval marks a significant advancement for providing quality and affordable treatment options to adults suffering from rheumatoid arthritis. Hence, the increasing biosimilar approvals by government bodies are favouring the biosimilars market growth.
In May 2023, Biocon Biologics and Viatris announced the availability of Abevmy® (bBevacizumab) in Canada. Abevmy® is a biosimilar to Roche’s Avastin® (Bevacizumab) and is the companies’ third biosimilar in the country. The biosimilar has been approved for four oncology indications by Health Canada and expands the accessibility to affordable biologics for cancer care.
In May 2023, Sandoz introduced ‘Act4Biosimilars’, a global initiative to address health inequality and inequity. The initiative would increase patients’ access to advanced medicines by improving the accessibility, approvability, affordability, and accessibility of biosimilars. Such initiatives are likely to favour the biosimilars market growth.
In March 2023, Samsung Bioepis and Biogen Canada Inc. announced that the biosimilar referencing LUCENTIS®I (ranibizumab), BYOOVIZ™, was approved by Health Canada. This would enable its use in the affordable treatment of retinal vascular disorders and as an anti-VEGF (vascular endothelial growth factor).
In February 2023, Biocon Biologics announced the acquisition of the biosimilar assets of Viatris to create one of the leading vertically-integrated and global companies. The acquisition would enable Biocon to gain Viatris’ portfolio of in-licensed biosimilar assets and accelerate its commercialisation strategy for biosimilars. Such mergers and acquisitions are accelerating the biosimilars market development.
In February 2023, Pfizer Inc. announced that its supplemental application for the interchangeability of ABRILADA™ (adalimumab-afzb) with Humira® (adalimumab) was accepted for review by the FDA. The interchangeability designation would enable ABRILADA™ to support the growing use of biosimilars while broadening the accessibility to quality and affordable treatment for chronic inflammatory issues.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Biosimilars refer to biologic products that have the same active properties as biologic drugs. They are integral in reducing healthcare costs and enhancing patient outcomes. Biosimilars are effective, safe, and cost-effective, due to which they are increasingly used as substitutes for biologics. Moreover, due to the impact of the COVID-19 pandemic and the rising focus on boosting the accessibility of critical drugs, the development of biosimilars is increasing.
The evolving regulatory environments in countries like Japan, the United States, and China are boosting the approval of biosimilars.
Biosimilars are cost-effective and expand the accessibility of biological medicines, due to which their demand is increasing.
Leading health authorities such as the FDA are increasingly approving interchangeable biosimilars to enhance the treatment accessibility of patients with serious medical conditions.
Several companies are investing in R&D activities to drive innovations in biosimilars development while reducing the overall cost of biosimilars manufacturing.
The widespread misinformation regarding the safety, science, and efficacy of biosimilars can create confusion and reduce their adoption.
The manufacturing of biosimilars is complicated and tedious and requires extensive R&D activities, which is likely to pose a challenge to the market.
Various regulatory challenges are associated with biosimilars due to the unavailability of reference products, issues with interchangeability, lack of resources, and problems associated with their quality.
By molecule, the market can be divided into infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa. Based on manufacturing, it can be bifurcated into in-house manufacturing and contract manufacturing. By indication, the market is segmented into auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America, the Middle East and Africa, Latin America, and the Asia Pacific are the major regional markets for biosimilars. The comprehensive EMR report offers an in-depth biosimilars market assessment that is based on the Porter's five forces model and provides a SWOT analysis.
The report provides a detailed analysis of the following leading companies in the market while covering their latest developments like mergers, acquisitions, investments and expansion plans as well as competitive landscape.
The oncology segment represents a considerable share of the market for biosimilars due to the growing prevalence of cancer. The increasing attempt by governments and pharmaceutical companies to reduce costs associated with cancer treatment is also boosting the demand for biosimilars. Furthermore, the surging clinical trials of biosimilars in cancer treatment are likely to offer lucrative growth opportunities to the biosimilars market.
The growth of the auto-immune diseases segment can be attributed to the growing prevalence of chronic issues such as multiple sclerosis, inflammatory bowel disease (IBD), and rheumatoid arthritis, among others. This, in turn, is likely to boost the demand for biosimilars on account of their quality treatment and cost-effectiveness.
The rising cases of type 2 diabetes and the increasing demand for affordable life-saving insulin and other drugs are propelling the growth of the diabetes segment. The segment of the biosimilars market is further fuelled by the growing awareness regarding the efficacy and safety of biosimilar insulins and the surging approvals of interchangeable biosimilar insulins.
The blood disorder segment is being aided by the growing incidences of sickle cell anaemia, leukaemia, and lymphoma, among others. Hence, the rising availability of biosimilars of critical biologics used in the treatment of such issues is augmenting the biosimilars market growth. Meanwhile, the growing use of biosimilars in growth hormone treatment is anticipated to aid the growth deficiency segment. The female infertility segment, in addition, is expected to be bolstered by the growing fertility issues and the increasing availability of biosimilar fertility treatments.
The market is growing on account of the rising use of molecules like insulin glargine, infliximab, etanercept, epoetin alfa, somatropin, filgrastim, follitropin alfa, and rituximab, to reduce healthcare costs. The increasing attempt to boost the accessibility to such molecules is anticipated to bolster the market growth.
Epoetin alfa accounts for a significant biosimilars market share owing to the growing use of its biosimilar in the treatment of anaemia, cancer, and chronic renal failure. Various health authorities are increasingly approving the use of biosimilars in surgical procedures for reducing the requirement for blood cell transfusions.
The demand for Insulin glargine is surging due to the rising prevalence of diabetes in adults, geriatrics, and children. Insulin is a life-saving drug for diabetics, which is boosting the demand for insulin glargine to lower the cost of insulin and enhance its accessibility. Moreover, health organisations such as the FDA are approving the use of insulin glargine biosimilars interchangeably, which is likely to aid the biosimilars market development.
The biosimilars of rituximab are increasingly used to treat leukaemia, autoimmune disorders, and lymphomas owing to their cost benefits and optimal quality. With the growing attempts to boost the accessibility of cancer treatment, various clinical trials and studies to enhance the efficiency of rituximab is expected to grow.
Various key players are increasingly outsourcing the manufacturing and development of biosimilars due to superior expertise and services provided by contract manufacturers. With the growing demand for real-world evidences to ensure the regulatory compliances of biosimilars, the contract manufacturing segment is likely to witness a healthy growth.
The in-house manufacturing segment is being supported by the increasing investments in the manufacturing capacities by the leading biosimilars market companies. For instance, in December 2020, Celltrion announced its plans to invest about $453 million in expanding its R&D and manufacturing site in Songdo, South Korea, to aid the biosimilars pipeline.
Europe holds a considerable share in the market for biosimilars on account of the establishment of solid frameworks for biosimilars adoption. The increasing approvals of biosimilars and the introduction of various initiatives to expand biosimilars competition by governments and purchasers are also aiding the market.
Several countries within Europe like Germany are also encouraging the prescriptions of biosimilars to enhance savings in the healthcare sector, which is augmenting the biosimilars market growth. Moreover, governments in the region are reducing unnecessary clinical data requirements for the approval of biosimilars to facilitate their launch.
The market in North America is witnessing robust growth due to the surging awareness regarding the safety, efficacy, and cost-effectiveness of biosimilars. The extensive adoption of biosimilars in oncology applications in the United States and Canada is further augmenting the market expansion. The growing utilisation of biosimilars in diabetes and ophthalmology treatment is further invigorating the market. In addition, some of the leading biosimilars market trends include the approval of interchangeable biosimilars and the increasing competition through the introduction of new biosimilars.
The increasing manufacturing of biosimilars in countries such as India and South Korea, among others, is expected to fuel the market in the Asia Pacific. With the rising healthcare costs associated with critical biologics, there is a growing approval of biosimilars to drive meaningful cost savings for both patients and healthcare organisations.
Countries such as Japan, Malaysia, and Australia, among others, are likely to address their biosimilars regulatory and legal framework and increase their approval. The rising acceptance of biosimilars in various countries like India, Japan, South Korea, and China, among others, is anticipated to lead to a surge in biosimilar launches over the forecast period. Furthermore, the biosimilars market development can be associated with the introduction of biosimilars for the treatment of various diseases and the rising availability of real-world data regarding their efficacy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Pfizer Inc. is one of the leading pharmaceutical companies that discovers, manufactures, and develops healthcare products, including innovative vaccines and medicines. The company aims to advance prevention, wellness, cures, and treatments for challenging critical diseases. In 2021, the company’s medicines and vaccines were used by approximately 1.4 billion people. Moreover, it initiated 13 clinical studies in 2021.
Celltrion Inc. is a pharmaceutical company based in Korea that introduced the "antibody biosimilar". It has broken ground in a number of previously unexplored areas, and it aims to expand as a global biopharmaceutical company. With sales in more than 90 countries and a production capacity of 190,000 litres, the company has a workforce of 2145 and revenue of USD 153 billion. Moreover, it is significantly boosting R&D activities to increase the biosimilars market demand.
Novartis AG is a pharmaceutical company that aims to extend and improve people’s lives by reimaging medicine. Its products are utilised by about 800 million people across the globe. With more than 108,000 employees, the company aims to deliver and discover new treatments and therapies. Its leading companies include Sandoz, Gyroscope Therapeutics, and Advanced Accelerator Applications.
AMGen Inc. is one of the major biotechnology companies. It focuses on areas with large unmet medical needs and uses its expertise to develop solutions offering improved health outcomes. It operates in over 100 countries in the world, and its breakthrough medications have helped millions of people combat critical illnesses.
Teva Pharmaceutical Industries Ltd. is a major generic drug and biopharmaceutical company. It is also a global leader in active pharmaceutical ingredients and speciality pharmaceuticals. The company has a presence in more than 60 markets globally and has a portfolio of approximately 3,000 medicines. With over 55 manufacturing facilities in more than 30 countries, the company serves nearly 200 million people every day.
Samsung Bioepis is a biopharmaceutical company that is focused on maximising the value of biosimilar products and medicines. It also aims to revolutionise the delivery of biologic therapeutics to patients as well as the biosimilars market. It employs more than 900 employees and oncology, immunology, ophthalmology, haematology, gastroenterology, and endocrinology are among the six major therapeutic areas of the company.
Biocon Ltd. is a global pharmaceutical company with a widespread presence all over the globe in over 120 countries. It is a pioneer in defining affordable and innovative approaches to treat diabetes, cancer, and autoimmune diseases. It has four major lines of business - biosimilars, generics, novel biologics, and research services, and employs over 12,000 people across the globe.
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product Type||
|Breakup by Drug Class||
|Breakup by Indications||
|Breakup by Procedure||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Biosimilars Market Overview
3.1 Global Biosimilars Market Historical Value (2017-2023)
3.2 Global Biosimilars Market Forecast Value (2024-2032)
4 Global Biosimilars Market Landscape
4.1 Global Biosimilars Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Biosimilars Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Drug Class
4.2.3 Analysis by Procedure
5 Global Biosimilars Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Biosimilars Market Segmentation
6.1 Global Biosimilars Market by Product Type
6.1.1 Recombinant Glycosylated Proteins
188.8.131.52 Monoclonal Antibodies
6.1.2 Recombinant Non-Glycosylated Proteins
184.108.40.206 Granulocyte Colony Stimulating Factors
6.2 Global Biosimilars Market by Drug Class
6.2.1 Market Overview
6.2.3 Recombinant Human Growth Hormone (RHGH)
6.2.4 Granulocyte Colony-Stimulating Factor
6.2.8 Monoclonal Antibodies
6.2.13 Enoxaparin Sodium
6.3 Global Biosimilars Market by Indications
6.3.1 Market Overview
6.3.2 Chronic Diseases
6.3.4 Autoimmune Diseases
6.3.5 Infectious Diseases
6.3.6 Blood Disorders
6.3.7 Growth Hormone Deficiency
6.4 Global Biosimilars Market by Procedure
6.4.1 Market Overview
6.5 Global Biosimilars Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Biosimilars Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Biosimilars Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Biosimilars Market
9.1 Market Share by Country
10 Latin America Biosimilars Market
10.1 Market Share by Country
11 Middle East and Africa Biosimilars Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2 Orion Pharma
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 Pfizer Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4 Samsung Bioepis
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5 Coherus BioSciences, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6 Amgen Inc.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Eli Lilly and Company.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 Takeda Pharmaceutical Company Limited.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9 Bristol-Myers Squibb Company
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.10 Merck KGaA
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.11 Teva Pharmaceutical Industries Ltd.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.13 Bayer AG
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.14 AbbVie Inc,
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.16 Dr. Reddy’s Laboratories Ltd.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.17 Boehringer Ingelheim International GmbH.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
18 Global Biosimilars Market- Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The global biosimilar market was valued at USD 24.5 billion in 2023.
The market is expected to grow at a CAGR of 17.60% from 2024 to 2032 to reach a value of USD 105.1 billion by 2032.
Biosimilars are likely to enhance innovations in the healthcare sector and increase the development of innovative drugs. Further, by boosting competitiveness between the key players, they are expected to enhance the accessibility to critical biologics and lower healthcare costs.
Biosimilars are made from biologic sources whereas generic drugs use chemicals as their primary sources. Moreover, biosimilars require special approval to be considered interchangeable while generic drugs are automatically interchangeable with biologics.
The market is being aided by the growing prevalence of various chronic diseases, the rising use of biosimilars in cancer treatment, and the increasing demand for cost-effective treatment methods.
The global biosimilars market is estimated to grow at a CAGR of 18.1% between 2024 and 2032.
The market is anticipated to be supported by the increasing research and development (R&D) activities, the surging approvals of biosimilars, and the growing introduction of new biosimilars.
Some of the major benefits of biosimilars include enhanced cost-effectiveness and efficacy of critical biologics. They also enable the reallocation of resources to other patient care requirements by providing affordable treatment options and improving treatment outcomes.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major molecules of biosimilars in the market are infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa.
The significant manufacturing segments in the market include contract and in-house manufacturing.
The various indications in the market for biosimilars are auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility.
The major players in the market are Pfizer Inc., Celltrion Inc., Novartis AG, AMGen Inc., Teva Pharmaceutical Industries Ltd., Samsung Bioepis, and Biocon Ltd., among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.